This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barter, P. Search for Related Content PubMed PubMed Citation Articles by Barter, P. Related Collections Animal models of human disease Risk Factors Lipid and lipoprotein metabolism

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2029.)
© 2000 American Heart Association, Inc.

Editorial

CETP and Atherosclerosis

Philip Barter

From the Department of Medicine, Royal Adelaide Hospital, Adelaide, Australia.

Correspondence to Philip Barter, University Department of Medicine, Royal Adelaide Hospital, Adelaide, South Australia 5000. E-mail pbarter@medicine.adelaide.edu.au

Key Words: : CETP • atherosclerosis • HDL

Ever since cholesteryl ester transfer protein (CETP) was first identified, there have been conflicting opinions regarding its role (if any) in the development of atherosclerosis. According to 1 view, CETP is antiatherogenic by virtue of its ability to increase the rate of reverse cholesterol transport (RCT), the pathway in which cholesterol in peripheral tissues is transported to the liver for elimination in bile. This pathway involves an initial uptake of cell cholesterol by HDL, where it is esterified before being transferred by CETP to LDL and VLDL. The cholesteryl esters in the VLDL/LDL pool are subsequently delivered to the liver and ultimately eliminated from the body as a component of bile. Thus, to the extent that CETP enhances the rate of RCT, it may be an antiatherogenic factor. However, the fact that CETP redistributes cholesteryl esters from the nonatherogenic HDL to the potentially atherogenic VLDL/LDL implies that it may also be proatherogenic.

The situation is even further complicated by mounting evidence that concentration-dependent, anti-inflammatory functions of HDL may also contribute to its antiatherogenicity.¹ Because CETP decreases the concentration of HDL,² it may decrease the anti-inflammatory impact of this lipoprotein fraction in a process that is ultimately proatherogenic. Thus, on theoretical grounds, CETP may be either proatherogenic or antiatherogenic, depending on which of the HDL functions is dominant. As outlined below, the situation has not been clarified by more direct studies in vivo in animals in which evidence supporting both a proatherogenic^{3 4 5} and an antiatherogenic^{6 7} role of CETP has been reported.

What Is CETP and What Does It Do?

. . . [Full Text of this Article]

This article has been cited by other articles:

				F. Apostolou, I. F. Gazi, A. Kostoula, C. C. Tellis, A. D. Tselepis, M. Elisaf, and E. N. Liberopoulos Persistence of an atherogenic lipid profile after treatment of acute infection with brucella J. Lipid Res., December 1, 2009; 50(12): 2532 - 2539. [Abstract] [Full Text] [PDF]

				G. Assmann and A. M. Gotto Jr HDL Cholesterol and Protective Factors in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-8 - III-14. [Abstract] [Full Text]

				P. Tontonoz and D. J. Mangelsdorf Liver X Receptor Signaling Pathways in Cardiovascular Disease Mol. Endocrinol., June 1, 2003; 17(6): 985 - 993. [Abstract] [Full Text] [PDF]

				K. L. Herron, S. Vega-Lopez, K. Conde, T. Ramjiganesh, N. S. Shachter, and M. L. Fernandez Men Classified as Hypo- or Hyperresponders to Dietary Cholesterol Feeding Exhibit Differences in Lipoprotein Metabolism J. Nutr., April 1, 2003; 133(4): 1036 - 1042. [Abstract] [Full Text] [PDF]

				P.N. Durrington, B. Mackness, and M.I. Mackness The Hunt for Nutritional and Pharmacological Modulators of Paraoxonase Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1248 - 1250. [Full Text] [PDF]

				K. L. Herron, S. Vega-Lopez, K. Conde, T. Ramjiganesh, S. Roy, N. S. Shachter, and M. L. Fernandez Pre-Menopausal Women, Classified as Hypo- or Hyper-Responders, do not Alter their LDL/HDL Ratio Following a High Dietary Cholesterol Challenge J. Am. Coll. Nutr., June 1, 2002; 21(3): 250 - 258. [Abstract] [Full Text] [PDF]

				A. L. Romero, K. L. West, T. Zern, and M. L. Fernandez The Seeds from Plantago ovata Lower Plasma Lipids by Altering Hepatic and Bile Acid Metabolism in Guinea Pigs J. Nutr., June 1, 2002; 132(6): 1194 - 1198. [Abstract] [Full Text] [PDF]

				M.C. Carr, A.F. Ayyobi, S.J. Murdoch, S.S. Deeb, and J.D. Brunzell Contribution of Hepatic Lipase, Lipoprotein Lipase, and Cholesteryl Ester Transfer Protein to LDL and HDL Heterogeneity in Healthy Women Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 667 - 673. [Abstract] [Full Text] [PDF]

				P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II Circulation, November 13, 2001; 104(20): 2498 - 2502. [Full Text] [PDF]

				J. Fan, H. Unoki, N. Kojima, H. Sun, H. Shimoyamada, H. Deng, M. Okazaki, H. Shikama, N. Yamada, and T. Watanabe Overexpression of Lipoprotein Lipase in Transgenic Rabbits Inhibits Diet-induced Hypercholesterolemia and Atherosclerosis J. Biol. Chem., October 19, 2001; 276(43): 40071 - 40079. [Abstract] [Full Text] [PDF]

				M.C. Carr, A.F. Ayyobi, S.J. Murdoch, S.S. Deeb, and J.D. Brunzell Contribution of Hepatic Lipase, Lipoprotein Lipase, and Cholesteryl Ester Transfer Protein to LDL and HDL Heterogeneity in Healthy Women Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 667 - 673. [Abstract] [Full Text] [PDF]